Upadacitinib for treating moderate rheumatoid arthritis

2.1 Upadacitinib (Rinvoq, AbbVie) is indicated 'for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to 1 or more disease-modifying antirheumatic drugs (DMARDs)'. Upadacitinib may be used as monotherapy or in combination with methotrexate.

2.2 The dosage schedule is available in upadacitinib's summary of product characteristics.

2.3 The list price for upadacitinib is £805.56 per 28‑day pack (company submission). The average cost for each patient per year is estimated at £10,508, based on the list price. The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.